Modulation of glucagon receptor pharmacology by receptor activity-modifying protein-2 (RAMP2)

Journal of Biological Chemistry

Volumn 290, Issue 38, 2015, Pages 23009-23022

  Weston, Cathryn ^a   Lu, Jing ^b   Li, Naichang ^b   Barkan, Kerry ^a   Richards, Gareth O ^c   Roberts, David J ^c   Skerry, Timothy M ^c   Poyner, David ^d   Pardamwar, Meenakshi ^e   Reynolds, Christopher A ^e   Dowell, Simon J ^f   Willars, Gary B ^b   Ladds, Graham ^a,g  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d ASTON UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF ESSEX   (United Kingdom)

^f GLAXOSMITHKLINE   (United Kingdom)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INTERACTIONS; LIGANDS; MAMMALS;

ADVERSE SIDE EFFECTS; BLOOD GLUCOSE LEVEL; CLINICAL EFFICACY; GLUCAGON-LIKE PEPTIDE-1; MAMMALIAN SYSTEMS; RECEPTOR ACTIVITY-MODIFYING PROTEINS; RECEPTOR SIGNALING; RECEPTOR-INTERACTING PROTEINS;

PROTEINS;

EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; LIGAND; LIRAGLUTIDE; LIXISENATIDE; OXYNTOMODULIN; RECEPTOR ACTIVITY MODIFYING PROTEIN 2; GLP1R PROTEIN, HUMAN; RAMP2 PROTEIN, HUMAN;

ALPHA CHAIN; ARTICLE; ASSAY; CONTROLLED STUDY; CROSS REACTION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG TARGETING; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; AGONISTS; GENETICS; HEK293 CELL LINE; METABOLISM;

GLUCAGON; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEK293 CELLS; HUMANS; LIGANDS; RECEPTOR ACTIVITY-MODIFYING PROTEIN 2;

EID: 84942860294     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.624601     Document Type: Article

References (50)

1. Habegger, K. M., and Heppner., K. M., Geary, N, Bartness, T.J., DiMarchi, R., and Tschöp, M. H. (2010) The metabolic actions of glucagon revisited. Nat. Rev. Endocrinol. 6, 689-697
2. Unger, R. H. (1985) Glucagon physiology and pathophysiology in the light of new advances. Diabetologia 28, 574-578
3. Scott, D. A., and Boye., K. S., Timlin, L., Clark, J. F., and Best, J. H. (2013) A network meta-analysis to compare glycemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. Diabetes Obes. Metab. 15, 213-223
4. Bagger, J. I., and Knop., F. K., Holst, J. J., and Vilsbøll, T. (2011) Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes Obes. Metab. 13, 965-971
5. Shen, D. M., Lin, S., and Parmee, E. R. (2011) A survey of small molecule glucagon receptor antagonists from recent patents (2006-2010). Expert Opin. Ther. Pat. 21, 1211-1240
6. Ahrén, B. (2009) Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev. Drug. Discov. 8, 369-385
7. i/o in HEK293 cells. J. Recept. Signal Transduct. Res. 29, 318-325
8. Kenakin, T., and Miller, L. J. (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev. 62, 265-304
9. Christopoulos, A., Christopoulos, G., Morfis, M., Udawela, M., Laburthe, M., Couvineau, A., Kuwasako, K., Tilakaratne, N, and Sexton, P. M. (2003) Novel receptor partners and function of receptor activity-modifying proteins. J. Biol. Chem. 278, 3293-3297
10. Wootten, D., Lindmark, H., Kadmiel, M., Willcockson, H., and Caron., K. M., Barwell, J., Drmota, T., and Poyner, D. R. (2013) Receptor activity modifying proteins (RAMPs) interact with the VPAC2 receptor and CRF1 receptors and modulate their function. Br. J. Pharmacol. 168, 822-834
11. McLatchie, L. M., and Fraser., N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., and Foord, S. M. (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393, 333-339
12. Hay, D. L., Christopoulos, G., Christopoulos, A., and Sexton, P. M. (2006) Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyr-idinyl)-l-piperazinyl] carbonyl] pentyl] amino]-1-[(3,5-dibromo-4-hy-droxyphenyl) methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3 (2H)-quin-azolinyl)(BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors: the role of receptor activity modifying protein 1. Mol. Pharmacol. 70, 1984-1991
13. Morfis, M., Tilakaratne, N, and Furness., S. G., Christopoulos, G., Werry, T. D., Christopoulos, A., and Sexton, P. M. (2008) Receptor activity-modifying proteins differentially modulate the G protein-coupling efficiency of amylin receptors. Endocrinology 149, 5423-5431
14. Coopman, K., Wallis, R., Robb, G., Brown, A. J. H, and Wilkinson., G. F., Timms, D., and Willars, G. B. (2011) Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor. Mol. Endocrinol. 25, 1804-1818
15. Coopman, K., Huang, Y., Johnston, N, and Bradley., S. J., Wilkinson, G. F., and Willars, G. B. (2010) Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent "compound 2" at the GLP-1 receptor. J. Pharmacol. Exp. Ther. 334, 795-808
16. Croft, W., Hill, C, McCann, E., Bond, M., Esparza-Franco, M., Bennett, J., Rand, D., Davey, J., and Ladds, G. (2013) A physiologically required GPCR-RGS interaction that compartmentalizes RGS activity. J. Biol. Chem. 288, 27327-27342
17. Weston, C, Poyner, D., Patel, V., Dowell, S., and Ladds, G. (2014) Investigating G protein signaling bias at the glucagon-like peptide-1 receptor in yeast. Br. J. Pharmacol. 171, 3651-3665
18. Dowell, S. J., and Brown, A. J. (2002) Yeast assays for G-protein-coupled receptors. Receptors Channels 8, 343-352
19. Brown, A. J., and Goldsworthy., S. M., Barnes, A. A., Eilert, M. M., Tcheang, L., Daniels, D., and Muir., A. I., Wigglesworth, M. J., Kinghorn, I., Fraser, N. J., Pike, N. B., Strum, J. C, Steplewski, K. M., Murdock, P. R., Holder, J. C, Marshall, F. H, Szekeres, P. G., Wilson, S., Ignar, D. M., Foord, S. M., Wise, A., and Dowell, S. J. (2003) The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 278, 11312-11319
20. Gietz, R. D., and Schiestl, R. H. (2007) High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat Protoc. 2, 31-34
21. Bertheleme, N, Singh, S., Dowell, S. J., Hubbard, J., and Byrne, B. (2013) Loss of constitutive activity is correlated with increased thermostability of the human adenosine A2A receptor 1. Br. J. Pharmacol. 169, 988-998
22. Usdin, T. B., and Hoare., S. R., Wang, T., Mezey, E., and Kowalak, J. A. (1999) TIP39: a new neuropeptide and PTH2-receptor agonist from hypothalamus. Nat Neurosci. 2, 941-943
23. Black, J. W., and Leff, P. (1983) Operational models of pharmacological agonism. Proc. R. Soc. Lond. B Biol. Sci. 220, 141-162
24. Bond, M., Croft, W., Tyson, R., Bretschneider, T., Davey, J., and Ladds, G. (2013) Quantitative analysis of human ras localization and function in the fission yeast Schizosaccharomycespombe. Yeast 30, 145-156
25. Grady, T., Fickova, M., Tager, H. S., Trivedi, D., and Hruby, V. J. (1987) Stimulation and inhibition of cAMP accumulation by glucagon in canine hepatocytes. J. Biol. Chem. 262, 15514-15520
26. Stewart, G. D., Valant, C, and Dowell., S. J., Mijaljica, D., Devenish, R. J., Scammells, P. J., Sexton P. M., and Christopoulos, A. (2009) Determination of adenosine A1 receptor agonist and antagonist pharmacology using Saccharomyces cerevisiae: implications for ligand screening and functional selectivity. J. Pharmacol. Exp. Ther. 331, 277-286
27. Brown, A. J., and Daniels., D. A., Kassim, M., Brown, S., Haslam, C. P., Terrell, V. R., Brown, J., Nichols, P. L., Staton, P. C, Wise, A., and Dowell, S. J. (2011) Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J. Pharmacol. Exp. Ther. 337, 236-246
28. Rudling, J. E., Kennedy, K., and Evans, P. D. (1999) The effect of site-directed mutagenesis of two transmembrane serine residues on agonist-specific coupling of a cloned human a 2A-adrenoceptor to adenylyl cyclase. Br. J. Pharmacol. 127, 877-886
29. Schepp, W., Dehne, K., Riedel, T., Schmidtler, J., Schaffer, K., and Classen, M. (1996) Oxyntomodulin: a cAMP-dependent stimulus of rat parietal cell function via the receptor for glucagon-like peptide-1 (7-36) NH2. Digestion 57, 398-405
30. Wynne, K., and Park., A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., and Bloom, S. R. (2005) Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects a double-blind, randomized, controlled trial. Diabetes 54, 2390-2395
31. Runge, S., and Wulff., B. S., Madsen, K., Bräuner-Osborne, H., and Knudsen, L. B. (2003) Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity. Br. J. Pharmacol. 138, 787-794
32. Jorgensen, R., Kubale, V., Vrecl, M., Schwartz, T. W., and Elling, C. E. (2007) Oxyntomodulin differentially affects glucagon-like peptide-1 receptor β-arrestin recruitment and signaling through Gα. J. Pharmacol. Exp. Ther. 322, 148-154
33. Hollenstein, K., de Graaf, C, Bortolato, A., Wang, M. W., Marshall, F. H., and Stevens, R. C. (2014) Insights into the structure of class B GPCRs. Trends Pharmacol. Sci. 35, 12-22
34. Shyu, J. F., Zhang, Z., Hernandez-Lagunas, L., Camerino, C, Chen, Y., Inoue, D., Baron, R., and Horne, W. C. (1999) Protein kinase C antagonizes pertussis-toxin-sensitive coupling of the calcitonin receptor to adenylyl cyclase. Eur. J. Biochem. 262, 95-101
35. Husmann, K., and Sexton., P. M., Fischer, J. A., and Born, W. (2000) Mouse receptor-activity-modifying proteins 1, -2 and -3: amino acid sequence, expression and function. Mol. Cell Endocrinol. 162, 35-43
36. Marks, J., and Debnam., E. S., Dashwood, M. R., Srai, S. K., and Unwin, R. J. (2003) Detection of glucagon receptor mRNA in the rat proximal tubule: potential role for glucagon in the control of renal glucose transport. Clin. Sci. 104, 253-258
37. Ali, S., and Ussher., J. R., Baggio, L. L., Kabir, M. G., Charron, M. J., Ilkayeva, O., Newgard, C. B., and Drucker, D. J. (2015) Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction. Mol. Metab. 4, 132-143
38. Totsune, K., Takahashi, K., Mackenzie, H. S., Murakami, O., Arihara, Z., Sone, M., Mouri, T., Brenner, B. M., and Ito, S. (2000) Increased gene expression of adrenomedullin and adrenomedullin-receptor complexes, receptor-activity modifying protein (RAMP)2 and calcitonin-receptor-like receptor (CRLR) in the hearts of rats with congestive heart failure. Clin. Sci. 99, 541-546
39. Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S. S., Drucker, D. J., and Husain, M. (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and - independent pathways. Circulation 117, 2340-2350
40. Sonne, D. P., Engstrøm, T., and Treiman, M. (2008) Protective effects of GLP-1 analogues exendin-4 and GLP-1 (9-36) amide against ischemia-reperfusion injury in rat heart. Regul. Pept. 146, 243-249
41. Cho, Y. M., and Merchant., C. E., and Kieffer, T. J. (2012) Targeting the gluca-gon receptor family for diabetes and obesity therapy. Pharmacol. Ther. 135, 247-278
42. Underwood, C. R., Garibay, P., Knudsen, L. B., Hastrup, S., Peters, G. H., Rudolph, R., and Reedtz-Runge, S. (2010) Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. J. Biol. Chem. 285, 723-730
43. Watkins, H. A., and Walker., C. S., Ly, K. N., Bailey, R. J., Barwell, J., Poyner, D. R., and Hay, D. L. (2014) Receptor activity-modifying protein-dependent effects of mutations in the calcitonin receptor-like receptor: implications for adrenomedullin and calcitonin gene-related peptide pharmacology. Br. J. Pharmacol. 171, 772-788
44. Siu, F. Y., He, M., de Graaf, C, Han, G. W., Yang, D., Zhang, Z., Zhou, C., Xu, Q., Wacker, D., Joseph, J. S., Liu, W., Lau, J., Cherezov, V., Katritch, V., Wang, M. W., and Stevens, R. C. (2013) Structure of the human glucagon class B G-protein-coupled receptor. Nature 499, 444-449
45. Koth, C. M., and Murray., J. M., Mukund, S., Madjidi, A., Minn, A., and Clarke., H. J., Wong, T., Chiang, V., Luis, E., Estevez, A., Rondon, J., Zhang, Y., Hötzel, I., and Allan, B. B. (2012) Molecular basis for negative regulation of the glucagon receptor. Proc. Natl. Acad. Sci. U.S.A. 109, 14393-14398
46. Booe, J. M., and Walker., C. S., Barwell, J., Kuteyi, G., Simms, J., and Jamaluddin., M. A., Warner, M. L., Bill, R. M., Harris, P. W., Brimble, M. A., Poyner, D. R., Hay, D. L., and Pioszak, A. A. (2015) Structural basis for receptor activity-modifying protein-dependent selective peptide recognition by a G protein-coupled receptor. Mol. Cell 58, 1040-1052
47. Hulme, E. C. (2013) GPCR activation: a mutagenic spotlight on crystal structures. Trends Pharmacol. Sci. 34, 67-84
48. Kruse, A. C, Hu, J., Pan, A. C, Arlow, D. H., Rosenbaum, D. M., Rosemond, E., Green, H. F., Liu, T., Chae, P. S., Dror, R. O., Shaw, D. E., Weis, W. I., Wess, J., and Kobilka, B. K. (2012) Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482, 552-556
49. Udawela, M., Christopoulos, G., Tilakaratne, N., Christopoulos, A., Albiston, A., and Sexton, P. M. (2006) Distinct receptor activity-modifying protein domains differentially modulate interaction with calcitonin receptors. Mol. Pharmacol. 69, 1984-1989
50. Quesada, I., Tudurí, E., Ripoll, C, and Nadal, A. (2008) Physiology of the pancreatic α-cell and glucagon secretion: role in glucose homeostasis and diabetes. J. Endocrinol. 199, 5-19